Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics

Figure 2

Subanalyses of patients with response to either decitabine or treatment choice (complete remission or complete remission with incomplete platelet recovery). P values were based on 2-sided Fisher’s exact test and stratified by age, cytogenetic risk, and Eastern Cooperative Oncology Group Performance Status. AML, acute myeloid leukemia; Aus., Australia; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; Med, median (months); NE, not estimable; OR, odds ratio; Resp, responder; TC, patient’s choice of treatment with physician’s advice.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us